Skip to content
Primary Menu
Technology
Clinical Data
Pipeline
About
Media
Contact
Media
News
Press
22/09/2025
BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer
News
Press
27/05/2025
BetaGlue® Announces ASCO Abstract Publication of the use of YntraDose® in an Advanced Large Animal Model of Pancreatic Cancer
News
Press
20/02/2025
BetaGlue® Completes Exclusive Global Agreement With Artivion
TM
Securing Supply Of BioGlue® For The Manufacture Of BetaGlue’s YntraDose® Oncology Platform
News
Press
16/12/2024
ENEA-Tech Biomedical Foundation Invests €6m in BetaGlue® Therapeutics Bringing 2024 Funding Round Total to €24m
News
Press
06/06/2024
BetaGlue® Adds €8m Equity Financing to €10m EIC Accelerator Award
News
Press
15/05/2024
BetaGlue® Therapeutics Announces the Appointment of Mike Cogswell as Chairman and Mike Maszy as Non-Executive Director
News
Press
30/04/2024
BetaGlue® Technologies SpA Announces Rebrand & Introduces YntraDose®
News
Press
04/03/2024
BetaGlue® Secures €10m EIC Accelerator Award
News
Press
15/01/2024
BetaGlue® Appoints Salvatore Calabrese as Chief Financial Officer
News
Press
27/02/2023
BetaGlue® renews the BoD: Dr Colin Story appointed CEO
News
20/10/2022
BetaGlue® strengthens its expertise in strategic areas with four new managers
News
03/10/2022
BetaGlue® published an article on the performance and safety of BAT-90 on ‘In Vivo’
